View in EDS HTML Full Text PDF Full Text

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.

Saved in:
Bibliographic Details
Title: Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Authors: Cousin S; Medical Oncology Department, Institut Bergonié, Bordeaux, France., Blay JY; Medical Oncology Department, Centre Léon Bérard, Lyon, France., Garcia IB; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institut of Oncology (VHIO), Barcelona, Spain., de Bono JS; The Institute of Cancer Research and Royal Marsden Hospital, London, UK., Le Tourneau C; Department of Drug Development and Innovation (D3i), INSERM U900 Research Unit, Institut Curie, Paris-Saclay University, Paris and Saint-Cloud, France., Moreno V; Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain., Trigo J; Medical Oncology Department, Hospital Universitario Virgen de la Victoria y Regional, IBIMA, Málaga, Spain., Hann CL; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Azad AA; Peter MacCallum Cancer Centre, Victoria, Australia., Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea., Cassier PA; Medical Oncology Department, Centre Léon Bérard, Lyon, France., French CA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Italiano A; Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France., Keedy VL; Department of Medicine, Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA., Plummer R; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK., Sablin MP; Department of Drug Development and Innovation (D3i), INSERM U900 Research Unit, Institut Curie, Paris-Saclay University, Paris and Saint-Cloud, France., Hemming ML; Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Ferron-Brady G; GSK, Collegeville, Pennsylvania, USA., Wyce A; GSK, Collegeville, Pennsylvania, USA., Khaled A; GSK, Collegeville, Pennsylvania, USA., Datta A; GSK, Collegeville, Pennsylvania, USA., Foley SW; GSK, Collegeville, Pennsylvania, USA., McCabe MT; GSK, Collegeville, Pennsylvania, USA., Wu Y; GSK, Collegeville, Pennsylvania, USA., Horner T; GSK, Collegeville, Pennsylvania, USA., Kremer BE; GSK, Collegeville, Pennsylvania, USA., Dhar A; GSK, Collegeville, Pennsylvania, USA., O'Dwyer PJ; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Source: International journal of cancer [Int J Cancer] 2022 Mar 15; Vol. 150 (6), pp. 993-1006. Date of Electronic Publication: 2021 Nov 26.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34724226
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Cousin+S%22">Cousin S</searchLink>; Medical Oncology Department, Institut Bergonié, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Blay+JY%22">Blay JY</searchLink>; Medical Oncology Department, Centre Léon Bérard, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Garcia+IB%22">Garcia IB</searchLink>; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institut of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22de+Bono+JS%22">de Bono JS</searchLink>; The Institute of Cancer Research and Royal Marsden Hospital, London, UK.<br /><searchLink fieldCode="AU" term="%22Le+Tourneau+C%22">Le Tourneau C</searchLink>; Department of Drug Development and Innovation (D3i), INSERM U900 Research Unit, Institut Curie, Paris-Saclay University, Paris and Saint-Cloud, France.<br /><searchLink fieldCode="AU" term="%22Moreno+V%22">Moreno V</searchLink>; Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Trigo+J%22">Trigo J</searchLink>; Medical Oncology Department, Hospital Universitario Virgen de la Victoria y Regional, IBIMA, Málaga, Spain.<br /><searchLink fieldCode="AU" term="%22Hann+CL%22">Hann CL</searchLink>; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Azad+AA%22">Azad AA</searchLink>; Peter MacCallum Cancer Centre, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Im+SA%22">Im SA</searchLink>; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Cassier+PA%22">Cassier PA</searchLink>; Medical Oncology Department, Centre Léon Bérard, Lyon, France.<br /><searchLink fieldCode="AU" term="%22French+CA%22">French CA</searchLink>; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Italiano+A%22">Italiano A</searchLink>; Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Keedy+VL%22">Keedy VL</searchLink>; Department of Medicine, Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Plummer+R%22">Plummer R</searchLink>; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.<br /><searchLink fieldCode="AU" term="%22Sablin+MP%22">Sablin MP</searchLink>; Department of Drug Development and Innovation (D3i), INSERM U900 Research Unit, Institut Curie, Paris-Saclay University, Paris and Saint-Cloud, France.<br /><searchLink fieldCode="AU" term="%22Hemming+ML%22">Hemming ML</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Ferron-Brady+G%22">Ferron-Brady G</searchLink>; GSK, Collegeville, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Wyce+A%22">Wyce A</searchLink>; GSK, Collegeville, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Khaled+A%22">Khaled A</searchLink>; GSK, Collegeville, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Datta+A%22">Datta A</searchLink>; GSK, Collegeville, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Foley+SW%22">Foley SW</searchLink>; GSK, Collegeville, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22McCabe+MT%22">McCabe MT</searchLink>; GSK, Collegeville, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Wu+Y%22">Wu Y</searchLink>; GSK, Collegeville, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Horner+T%22">Horner T</searchLink>; GSK, Collegeville, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Kremer+BE%22">Kremer BE</searchLink>; GSK, Collegeville, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Dhar+A%22">Dhar A</searchLink>; GSK, Collegeville, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22O'Dwyer+PJ%22">O'Dwyer PJ</searchLink>; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Shapiro+GI%22">Shapiro GI</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Piha-Paul+SA%22">Piha-Paul SA</searchLink>; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220042124%22">International journal of cancer</searchLink> [Int J Cancer] 2022 Mar 15; Vol. 150 (6), pp. 993-1006. <i>Date of Electronic Publication: </i>2021 Nov 26.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Liss%22">Wiley-Liss </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0042124 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0215 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200207136%22">00207136 </searchLink><i>NLM ISO Abbreviation: </i>Int J Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34724226
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/ijc.33861
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 993
    Titles:
      – TitleFull: Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Cousin S
      – PersonEntity:
          Name:
            NameFull: Blay JY
      – PersonEntity:
          Name:
            NameFull: Garcia IB
      – PersonEntity:
          Name:
            NameFull: de Bono JS
      – PersonEntity:
          Name:
            NameFull: Le Tourneau C
      – PersonEntity:
          Name:
            NameFull: Moreno V
      – PersonEntity:
          Name:
            NameFull: Trigo J
      – PersonEntity:
          Name:
            NameFull: Hann CL
      – PersonEntity:
          Name:
            NameFull: Azad AA
      – PersonEntity:
          Name:
            NameFull: Im SA
      – PersonEntity:
          Name:
            NameFull: Cassier PA
      – PersonEntity:
          Name:
            NameFull: French CA
      – PersonEntity:
          Name:
            NameFull: Italiano A
      – PersonEntity:
          Name:
            NameFull: Keedy VL
      – PersonEntity:
          Name:
            NameFull: Plummer R
      – PersonEntity:
          Name:
            NameFull: Sablin MP
      – PersonEntity:
          Name:
            NameFull: Hemming ML
      – PersonEntity:
          Name:
            NameFull: Ferron-Brady G
      – PersonEntity:
          Name:
            NameFull: Wyce A
      – PersonEntity:
          Name:
            NameFull: Khaled A
      – PersonEntity:
          Name:
            NameFull: Datta A
      – PersonEntity:
          Name:
            NameFull: Foley SW
      – PersonEntity:
          Name:
            NameFull: McCabe MT
      – PersonEntity:
          Name:
            NameFull: Wu Y
      – PersonEntity:
          Name:
            NameFull: Horner T
      – PersonEntity:
          Name:
            NameFull: Kremer BE
      – PersonEntity:
          Name:
            NameFull: Dhar A
      – PersonEntity:
          Name:
            NameFull: O'Dwyer PJ
      – PersonEntity:
          Name:
            NameFull: Shapiro GI
      – PersonEntity:
          Name:
            NameFull: Piha-Paul SA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 03
              Text: 2022 Mar 15
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1097-0215
          Numbering:
            – Type: volume
              Value: 150
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: International journal of cancer
              Type: main
ResultId 1